Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 + MK-8742 in chronic hepatitis C with Child-Pugh B cirrhosis
NL-OMON41892Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of grazoprevir and verubecestat in hepatitis C virus infection (3 arms), sponsored by Merck & Co. Primary endpoints: SVR12 and Safety and tolerability. Planned start Dec 2014; status: withdrawn.
02
Drugs
grazoprevirverubecestat
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON41892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41892.